SCHEMBL646809

SCHEMBL646809

CC[CH]N1CCCC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1219974 0.94 BRD4 (0.37)
SCHEMBL6860222 0.79 PIK3CD (0.41)
SCHEMBL6543603 0.79 PIK3CD (0.41)
SCHEMBL11976728 0.79 PIK3CD (0.41)
SCHEMBL4551201 0.78
SCHEMBL1569225 0.78 BRD4 (0.39)
SCHEMBL7625864 0.78 BRD4 (0.34)
SCHEMBL430003 0.77 ALOX5 (0.41)
SCHEMBL649628 0.75
SCHEMBL5115443 0.74 CHRM2 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210330678-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-10-28 US claimed
EP-3846808-A2 PAPD5 INHIBITORS AND METHODS OF USE THEREOF CHILDREN'S MEDICAL CENTER CORPORATION (US) 2021-07-14 EP claimed
US-9949966-B2 Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection HOFFMAN-LA ROCHE INC. (US) 2018-04-24 US claimed
EP-3099685-B1 NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN LA ROCHE (CH) 2018-04-18 EP claimed
EP-3099685-A1 NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. Hoffmann-La Roche AG (CH) 2016-12-07 EP claimed
US-20160296515-A1 NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN-LA ROCHE INC. (US) 2016-10-13 US claimed
US-9458153-B2 Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection HOFFMANN-LA ROCHE INC. (US) 2016-10-04 US claimed
US-20160207914-A9 Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection HOFFMANN-LA ROCHE INC. (US) 2016-07-21 US claimed
WO-2015113990-A1 NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2015-08-06 WO claimed
US-20150210682-A1 Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection HOFFMANN-LA ROCHE INC. (US) 2015-07-30 US claimed
US-20040186116-A1 such as 2-(7-acetylamino-1-furano-2-ylmethyl-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-succinic acid; for treatment of autoimmune diseases, proliferative diseases, angiogenic disorders, and/or cancers; catheters, prosthetics VERTEX PHARMACEUTICALS INCORPORATED 2004-09-23 US claimed
WO-2004064741-A2 COMPOUNDS, COMPOSITIONS, AND METHODS CYTOKINETICS INC. (US) 2004-08-05 WO claimed
WO-2004060878-A2 INHIBITORS OF PHOSPHATASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-07-22 WO claimed
US-20040023996-A1 Methods and compositions utilizing quinazolinones CYTOKINETICS, INC. 2004-02-05 US claimed
US-6562831-B1 Inhibitors of the mitotic kinesin KSP and are useful in the treatment of cellular proliferative diseases CYTOKINETICS, INC. 2003-05-13 US claimed
EP-1296959-A1 METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES Cytokinetics, Inc. (US) 2003-04-02 EP claimed
WO-2001030768-A9 METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES CYTOKINETICS INC (US) 2002-08-15 WO claimed
EP-1226129-A1 METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES Cytokinetics, Inc. (US) 2002-07-31 EP claimed
WO-2001098278-A1 METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES CYTOKINETICS, INC. (US) 2001-12-27 WO claimed
WO-2001030768-A1 METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES CYTOKINETICS, INC. (US) 2001-05-03 WO claimed